Global Glioblastoma Multiforme Treatment Market to reach USD 3.81 Billion by 2027.Global Glioblastoma Multiforme Treatment Market is valued approximately at USD 2.14 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.6% over the forecast period 2021-2027. Glioblastoma Multiforme is a severe form of cancer which begins within the human brain. The global Glioblastoma Multiforme Treatment market is being driven by rising prevalence of glioblastoma multiforme and increase in incidences of brain tumors. Furthermore, the rising research and development, and growth in rate of approval for novel therapy and combination therapy will provide new opportunities for the global Glioblastoma Multiforme Treatment industry. For instance, according to National Brain Tumor society, in year 2020, there were 700,000 people suffering with primary brain tumor in the United States and it is anticipated that approximately 85,000 more people will be diagnosed by year end 2021. Also, in June 2019, the U.S. FDA had approved Pfizer's Zirabev, which is a biosimilar for Avastin, and used for the treatment of the recurrent glioblastoma, colorectal cancer and NSCLC, and among others. Also, in July 2020, the U.S. FDA granted fast track approval for designation to Denovo biopharma's DB102 (enzastaurin) to treat new patients who are diagnosed with glioblastoma. As a result, increased approvals for novel therapy and combination therapy will serve as a catalyst for the Glioblastoma Multiforme Treatment industry in the future. However, lack of effective therapies for glioblastoma multiforme and high cost associated with the development of drug and stringent regulations, may impede market growth over the forecast period of 2021-2027.

Asia Pacific, North America, Europe, Latin America, and Rest of the World are the key region considered for the global Glioblastoma Multiforme Treatment Market. Strong government support in order for the development of healthcare sector, rising awareness about the rare disorders, and easy accessibility of quality medical facility makes North America the leading region across the world in terms of market share. Whereas Asia pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector in the region.
Major market player included in this report are:

Merck & Co., Inc.
Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Hoffmann-La Roche Ltd.
Pfizer, Inc.
Amgen, Inc.
Arbor Pharmaceuticals, LLC
Amneal Pharmaceuticals
Karyopharm Therapeutics, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Tumor Treating Fields Therapy
Immunotherapy
By Drug class:
Temozolomide
Bevacizumab
Lomustine
Carmustine Wafers
Others
By End use:
Hospitals
Clinics
Ambulatory Surgical Centers


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Glioblastoma Multiforme Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors